Tata Elxsi has launched AnaTel, an AI-native software development platform designed specifically for healthcare and medical technology companies.

Built in partnership with OpenAna, AnaTel aims to speed up software development, automate regulatory documentation, and cut development cycles for medical devices and Software as a Medical Device (SaMD) by up to 60 per cent.

What makes AnaTel different

Most AI tools for developers focus mainly on code generation. AnaTel is positioned as an end-to-end engineering execution platform for regulated environments. It embeds autonomous AI agents directly into the software engineering workflow, covering the full lifecycle from requirements and architecture to deployment, verification, validation, and continuous optimisation. This makes it more like a configurable AI software team than a simple coding

The platform uses a dedicated Healthcare and Life Sciences expert agent fine-tuned for medtech regulatory and engineering contexts. It generates code, documentation, test cases, and regulatory artefacts as part of day-to-day work, rather than as an afterthought.

Impact on development timelines and productivity

Tata Elxsi says AnaTel can reduce Software as a Medical Device (SaMD) development and change assessment timelines from nearly eight weeks to about 72 hours. The company claims engineering productivity improvements of up to 60% for teams using the platform. This is significant in a field where long development cycles and heavy documentation requirements often slow down innovation.
These gains come as medical device regulators, including the US FDA and European authorities, are tightening rules around AI-enabled medical software and documentation standards. Faster, more consistent documentation can help companies meet these requirements without overloading engineering teams.

Regulatory support and documentation features

AnaTel is designed to handle the complex documentation needs of medical device software. It supports eSTAR-aligned submission preparation, creates requirements traceability matrices, and generates verification and validation evidence along with audit-trail documentation. These outputs are produced as part of routine engineering rather than as separate compliance exercises. For companies preparing for regulatory submissions or audits, this reduces the manual effort and risk of human error.

AnaTel makes its debut at DeviceTalks Boston 2026, where Tata Elxsi is showcasing its latest advances in AI-powered MedTech engineering and compliance. The platform reflects a broader shift toward AI-native healthcare software engineering, bringing automation into highly regulated development and compliance workflows. For medical device and SaMD companies, AnaTel offers a practical way to use AI for both building software and meeting regulatory expectations, without turning compliance into a separate, time-consuming process.